The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis

Alcoholism: Clinical and Experimental Research

Volumn 28, Issue 1, 2004, Pages 51-63

  Mann, Karl ^a   Lehert, Philippe ^b   Morgan, Marsha Y ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Facultes Universitaires Catholiques de Mons   (Belgium)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alcohol Dependency; Alcohol Drinking; Meta Analysis; Randomized Controlled Trials; Treatment Outcome

Indexed keywords

ACAMPROSATE; PLACEBO;

ABSTINENCE; ALCOHOLISM; CLINICAL TRIAL; DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; REVIEW; TREATMENT OUTCOME;

ALCOHOLISM; CONFIDENCE INTERVALS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TAURINE; TEMPERANCE;

EID: 1642576316     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ALC.0000108656.81563.05     Document Type: Review

References (68)

1. Al Quatari M, Bouchenafa O, Littleton J (1998) Mechanisms of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 22:810-814.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. 3rd ed, rev. American Psychiatric Association, Washington, DC.
3. American Psychiatric Association (1990) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. American Psychiatric Association, Washington, DC.
4. Ansoms C, Deckers F, Lehert P, Pelc I, Potgeiter A (2000) An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome. Eur Addict Res 6:132-140.
5. Anton RF (2001) Pharmacological approaches to the management of alcoholism. J Clin Psychiatry (Suppl 20) 62:11-17.
6. Anton RF, Swift RM (2003) Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict (Suppl 1) 12:S53-S68.
7. Babor T, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, Grube J, Gruenewald P, Hill L, Holder H, Homel R, Österberg E, Rehm J, Room R, Rossow I (2003) Alcohol: No Ordinary Commodity-Research and Public Policy. Oxford University Press, Oxford and London.
8. Bäckström S, Bachteler D, Koch S, Hyytiä P, Spanagel R (2004) The mGluR5 antagonist MPEP prevents alcohol seeking and relapse behavior. Eur J Neurosci, in press.
9. Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter AS, Teixeira de Sousa E (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatr Clin 18:149-160.
10. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573-579.
11. Brockwell SE, Gordon IR (2001) A comparison of statistical methods for meta-analysis. Stat Med 20:825-840.
12. Bronisch T, Wittchen HU (1992) Lifetime and 6-month prevalence of abuse and dependence of alcohol in the Munich follow-up study. Eur Arch Psychiatry Clin Neurosci 241:273-282.
13. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A (1981) A method for assessing the quality of a randomized control trial. Control Clin Trials 2:31-49.
14. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neurosci 4:873-874.
15. Chick J, Howlett H, Morgan MY, Ritson B (2000) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35:176-187.
16. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test, BMJ 315:629-634.
18. Feeney GF, Young RM, Connor JP, Tucker J, McPherson A (2002) Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term outcomes for alcohol dependence improved? Aust NZ J Psychiatry 36:622-628.
19. Fuchs W-J, Riebenfeld D (2002) Acamprosate and psychosocial support an integrated approach to the prevention of relapse in alcohol-dependent patients in Switzerland. Schweiz Rundsch Med Prax 91:735-742.
20. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999) Pharmacological treatment of alcohol dependence: a review of the evidence JAMA 281:1318-1325.
21. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. Eur Addict Res 3:129-137.
22. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M. (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res Clin Exp 52:291-295.
23. Grant BF (1997) Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States. J Stud Alcohol 58:464-473.
24. Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 36:413-418.
25. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu MC, Hart SR, Pedigo NW, Littleton JM (2002) Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 26:1779-1793.
26. Hedges LV, Olkin I (1985) Statistical Methods for Meta-Analysis. Academic Press, New York.
27. Hillemond B, Lhuintre JP, Steru L, Boismare F, Daoust M, Moore N, et al. (1989) Multicenter trial of calcium bis (acetylhomotaurinate) in treatment of alcohol dependence. Rev Alcohol 34:9-28.
28. Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS (2002) Naltrexone and acamprosate: meta-analysis of two medical treatments for alcohol ism. Alcohol Clin Exp Res (Suppl) 26:130A, 751.
29. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92-99.
30. Kraemer HC, Andrews G (1982) A non parametric technique for meta-analysis effect size calculation. Psychol Bull 91:404-412.
31. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335-1341.
32. Ladewig D, Knecht T, Leher P, Fendl A (1993) Acamprosate-a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umscl 50:182-188.
33. Lehert P (1993) Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl 2:157-163.
34. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Boismare F, Hillemand B (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1:1014-1016.
35. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F, Hillemand B (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25:613-622.
36. Littleton J, Zieglgänsberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict (Suppl 1) 12:S3-S11.
37. Mason BJ (2001) Results of the multicenter study of acamprosate in the treatment of alcoholism (abstract). Biol Psychiatry (Suppl 8) 48:77S
38. Mason BJ (2003) Acamprosate. Recent Dev Alcohol 16:203-215.
39. Monahan S, Finney JW (1996) Explaining abstinence rates following treatment for alcohol abuse: a quantitative synthesis of patient, research design and treatment effects. Addiction 91:787-805.
40. Moncrieff J, Drummond DC (1998) The quality of alcohol treatment research: an examination of influential controlled trials and development of a quality rating system. Addiction 93:811-823.
41. Moyer A, Finney JW, Swearingen CE (2002) Methodological characteristics and quality of alcohol treatment outcome studies, 1970-98: an expanded evaluation. Addiction 97:253-263.
42. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M (1998) Mechanisms of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 22:802-809.
43. Namkoong K, Lee B-O, Lee P-G, Choi M-J, Lee E (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 38:135-141.
44. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30:239-247.
45. Pelc I, Ansoms C, Lehert P, Fischer F, Fuchs W, Landron F, Preto AJP, Morgan MY (2002) The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res 26:1529-1538.
46. Pelc I, Le Bon O, Verbanck P, Lehert PH, Opsomer L (1992) Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study, in Novel Pharmacological Interventions for Alcoholism (Naranjo C, Sellers E eds), pp 348-352. Springer Verlag, New York.
47. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73-77.
48. Pignone M, Phillips C, Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ 321:983-986.
49. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537-1546.
50. Popp RL, Lovinger DM (2000) Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Neurosci 394:221-231.
51. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J (2001) The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40:749-760.
52. Reynaud M, Gaudin-Colombel AF, Le Pen C (2001) Two methods of estimating health cost linked to alcoholism in France (with a note on social cost). Alcohol Alcohol 36:89-95.
53. Rice DP (1993) The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World 17:10-11.
54. Roussaux JP, Hers D, Ferauge M (1996) Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 51:65-68.
55. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T (2001) Naltrexone versus acamprosate: one year follow-up of alcohol dependence of alcohol dependence treatment. Alcohol Alcohol 36:419-425.
56. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsey LE (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 85:265-271.
57. Sass H, Soyka M, Mann K, Zieglgänsberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673-680.
58. Schoechlin C, Engel RR (2000) Meta-analysis of pharmotherapeutic trials, in Handbook of Alcoholism (Zernig G, Saria A, Kurz M, O'Malley S eds), pp 339-351. Innsbruck University Press, Innsbruck, Austria.
59. Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Macpherson K, Parrott S, Quinn S, Tochel C, Watson H (2003) Prevention of Relapse in Alcohol Dependence. Health Technology Assessment Report 3. Health Technology Board of Scotland, Glasgow.
60. Smolka MN, Kiefer F, Mann K (2003) Advances in the treatment of alcohol dependence; Pharmacological relapse prevention (in German). MMW-Fortsch Medizin 145:65-69.
61. Soyka M, Chick J (2003) Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. Am J Addict (Suppl 1) 12:S69-S80.
62. Soyka M, Preuss U, Schuetz C (2002) Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results of a non-blind, multicentre study. Drugs R D 3:1-12.
63. Soyka M, Sass H (1994) Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism-preliminary data. Alcohol Alcohol Suppl 2:531-536.
64. Swift RM (1999) Drug therapy for alcohol dependence. N Engl J Med 340:1482-1487.
65. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35:202-209.
66. Thornley B, Rathbone J, Adams CE, Awad G (2003) Chlorpromazine versus placebo in schizophrenia. Cochrane Database Syst Rev 2:CD00028.4.
67. Wagenaar AC, Harwood EM, Toomey TL, Denk CE, Zander KM (2000) Public opinion on alcohol policies in the United States: results from a national survey. J Public Health Policy 21:303-327.
68. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438-1442.